New Drug Enables Spinal Cord to Repair Itself
Clinical Trial of NVG-291 at Shirley Ryan AbilityLab
January 19, 2022
Injections of a new drug that enabled paralyzed animals to recover mobility and/or bladder function will begin clinical trials at the Shirley Ryan AbilityLab in Chicago in the second half of this year. The trial will treat both patients with new spinal cord injuries and those with an injury more than three years old.
Two independent studies, recently published in the important scientific journals, Nature and Experimental Neurology, found that NVG-291, a treatment developed by the biotech company, NervGen, substantially reversed spinal cord injury damage in rats. This video, created by NervGen, tells the story.
The new drug is based on the groundbreaking work of neuroscientist Dr. Jerry Silver at Case Western Reserve University, who has spent almost 40 years in spinal cord injury research. Dr. Silver discovered a class of molecules, called chondroitin sulfate proteoglycans, or CSPGs, are present in the scar that forms after the nervous system is injured. The CSPGs prevent the nervous system from repairing itself. NVG-291 was designed to bypass the obstruction and enable the nervous system’s natural repair mechanisms, including plasticity and regeneration of the nerves’ myelin sheath.
“We have been following Dr. Silver’s work for years and are very excited to be the first center working with NervGen on this important spinal cord injury study,” said Monica A. Perez, PT, PhD, Scientific Chair of the Arms + Hands Lab at Shirley Ryan AbilityLab in Chicago. “The ability of NVG-291 to demonstrate meaningful recovery in motor function, sensory function and bladder control in animal models is exceptional. If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury.”
NVG-291-R results already demonstrated in animal studies include:
- Locomotive recovery with a various types of spinal cord injured animals achieving near complete recovery
- 100% of spinal-cord- injured animals experienced partial or complete recovery of bladder function at the higher doses tested
- The results were reproduced in multiple studies, labs and preclinical models, including several separate spinal cord injury studies
- Functional improvement in locomotive and bladder functions was lasting and durable, even after a limited period of daily injections
- NVG-291-R was found to be relatively simple and non-invasive to administer
For much more about how the clinical trial works and what to expect from this class of drug in the future visit – https://tinyurl.com/ywm5uykm